Regeneron (REGN) Tops Q2 EPS by 39c, beats revenue
Tweet
Share
E-mail
Get Alerts REGN Hot Sheet
Price: $735.20 +0.05%
Revenue Growth %: +21.1%
Financial Fact:
Research and development: 543.05M
Today's EPS Names:
TAYD, PKE, More
Revenue Growth %: +21.1%
Financial Fact:
Research and development: 543.05M
Today's EPS Names:
TAYD, PKE, More
Join SI Premium – FREE
Regeneron (NASDAQ: REGN) reported Q2 EPS of $10.24, $0.39 better than the analyst estimate of $9.85. Revenue for the quarter came in at $3.16 billion versus the consensus estimate of $3.03 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rivian reports record Q3 deliveries, beats estimates, shares rise
- Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)
- Integra LifeSciences stock tumbles after cutting 2026 outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
